Abselion Expands Amperia Platform for Broader Research Applications

Published: 24 Sep 2025

Author: Precedence Research

Share :

A life sciences technology innovator, Abselion, has announced its new product for the Amperia benchtop platform, the Protein G Total Antibody Quantification Kit. This new issue significantly enhances the platform's utility by enabling precise quantification. The broader array of antibody isotypes and species that its current Protein A-based format cannot accommodate. By incorporating this, researchers now have the flexibility and precision of antibody-based experiments, along with the same simplified workflow and high-sensitivity electrochemical detection that Amperia is known for.

The kit comes in a ready-to-use format, featuring protein G-coated sensor strips, detection reagents, buffers, and plates. The system is compatible with Amperia's guided software to provide researchers. With the chance to produce high-quality antibody titre data without dedicating particular training or expansive lab facilities. The simplification of the processes involved in conventional quantification techniques. This enables laboratories to accelerate the discovery process and streamline workflows in both research and process development settings.

The launch of the Protein G kit highlights Abselion's commitment to democratizing more complex analysis processes in antibody research and biologics development. The company enhances the quantification of Amperia, enabling scientists to make decisions more quickly and with greater information in the fields of therapeutic development, diagnostics, and scholarly research. This innovation fulfills the increasing need for flexible solutions capable of adapting to the evolving requirements of antibody discovery, bioprocess optimization, and quality control. Furthermore, the company has signalled its intention to keep growing the Amperia ecosystem by adding new kits and tools. This further enables scientists to accommodate a wide range of antibody formats, subclasses, and therapeutic modalities.

Executive’s Statement:

Dr. Ruizhi Wang, Founder and CEO of Abselion:

“Antibody-based research and development often involves a wide variety of formats, subclasses, and species. Having the flexibility to choose the most appropriate assay without adjusting workflows can simplify decision-making and improve efficiency. This launch reflects Abselion’s commitment to evolving its platform in response to real-world research needs. Expanding our antibody quantification offering with Protein G allows us to support better scientists working with a broader range of antibody formats. It reflects our ongoing focus on making practical, application-driven tools more accessible.”